Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.

导出 OA

翻译打印收藏纠错

作者： Daniel M,Geynisman ^[1] ; Mauricio,Burotto ^[2] ; Camillo,Porta ^[3] ; Cristina,Suarez ^[4] ; Maria T,Bourlon ^[5] ; Stephen,Huo ^[6] ; Viviana,Del Tejo ^[7] ; Ella X,Du ^[8] ; Xiaoran,Yang ^[8] ; Keith A,Betts ^[8] ; Toni K,Choueiri ^[9] ; Bradley,McGregor ^[10]

作者单位： Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. ^[1] Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile. ^[2] Interdisciplinary Department of Medicine, University of Bari 'A.Moro' and Division of Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy. ^[3] Medical Oncology, Vall d' Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d' Hebron, Vall d' Hebron Barcelona Hospital Campus, Barcelona, Spain. ^[4] Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ^[5] Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA. ^[6] US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA. ^[7] Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA. ^[8] Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. ^[9] Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. bradley_mcgregor@dfci.harvard.edu. ^[10]